التفاصيل البيبلوغرافية
| العنوان: |
High-Risk Recurrence Basal Cell Carcinoma: Focus on Hedgehog Pathway Inhibitors and Review of the Literature. |
| المؤلفون: |
Campione, Elena, Di Prete, Monia, Lozzi, Flavia, Lanna, Caterina, Spallone, Giulia, Mazzeo, Mauro, Cosio, Terenzio, Rapanotti, Cristina, Dika, Emi, Gaziano, Roberta, Orlandi, Augusto, Bianchi, Luca |
| المصدر: |
Chemotherapy (0009-3157); 2020, Vol. 65 Issue 1-2, p2-10, 9p |
| مصطلحات موضوعية: |
BASAL cell carcinoma, BASAL cell nevus syndrome, LITERATURE reviews, HEDGEHOG signaling proteins, PATHOLOGY, CLINICAL trials |
| الشركة/الكيان: |
EUROPEAN Medicines Agency, UNITED States. Food & Drug Administration |
| مستخلص: |
Basal cell carcinoma is the most common skin tumour, with the majority of the cases occurring on the head and neck district, where cosmetic and functional results are crucial. It can be locally destructive if not diagnosed early and treated appropriately. Surgery is the treatment of choice for most lesions, but aggressive, recurrent, or unresectable tumours can be challenging to manage. Advanced basal cell carcinoma includes high recurrence risk subtypes, in which standard therapies demonstrate lack of efficacy. This led to a need for investigating more deeply the pathogenesis of the disease and to the discovery of the implication of the hedgehog pathway. The development of systemic inhibitors of this pathway provides new treatment options for patients with advanced disease, resulting in survival improvement. Food and Drug Administration, before, and European Medicines Agency later approved 2 Hedgehog pathway inhibitors for the treatment of advanced basal cell carcinomas, vismodegib and sonidegib. Here, we present a review of the current English language literature trying to analyze differences in the 2 drugs as a head-to-head comparison between them has not already been documented in a randomized controlled clinical trial. Although vismodegib and sonidegib showed similar efficacy and safety profiles, in an indirect comparison scenario, sonidegib has shown slightly better outcomes in locally advanced basal cell carcinoma than vismodegib. They present different molecular structures, as they bind different residues on their targets and develop resistance for different mutations. In a future scenario, clinical trials comparing the 2 drugs are needed, as well as expanding data on discontinuation of therapy and/or consequential administration of them, with the aim to improve our clinical practise. [ABSTRACT FROM AUTHOR] |
|
Copyright of Chemotherapy (0009-3157) is the property of Karger AG and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
